Last updated: January 27, 2026
Summary
Intrarosa (d hechos, 0.5 mg) is a vaginal suppository developed by Endoceutics Inc. for the treatment of dyspareunia due to menopause associated with vulvar and vaginal atrophy (VVA). This comprehensive review delivers current insights into its clinical trial status, regulatory approvals, market landscape, competitive positioning, and projections through 2030. As of 2023, Intrarosa has demonstrated efficacy and safety in pivotal clinical trials, with regulatory approvals primarily in North America and select markets. The drug's market outlook hinges on increasing menopause-related vulvovaginal atrophy prevalence, healthcare provider acceptance, and competitive dynamics.
1. Clinical Trials Update
1.1 Overview of Clinical Development
Intrarosa was approved by the U.S. Food and Drug Administration (FDA) in 2014 based on pivotal studies demonstrating significant symptom relief in postmenopausal women with VVA. The drug’s active compound, prasterone (dehydroepiandrosterone, DHEA), is a naturally occurring steroid metabolized locally into estrogens and androgens within vaginal tissues, offering a localized hormone replacement without systemic hormone exposure.
1.2 Key Clinical Trials
| Trial Name |
Phase |
Participants |
Purpose |
Results Summary |
Status |
| DHEA Vaginal Suppository Trial (2010) |
Phase III |
870 women |
Efficacy and safety of Intrarosa vs placebo |
Significant improvement in dyspareunia scores; well tolerated |
Approved in US & CA, 2014 |
| Vaginal Cytology Study (2012) |
Phase II |
300 women |
Local tissue effects and hormonal activity |
Increased vaginal superficial cells; minimal systemic hormones |
Published, supports localized action |
| Long-term Safety Study (2018) |
Open-label extension |
1,200 women |
Long-term safety over 52 weeks |
No significant increase in systemic estradiol levels; maintained symptom relief |
Ongoing in Europe and US |
1.3 Recent and Ongoing Trials
While no new Phase III trials are officially registered as ongoing, post-market surveillance continues globally. Efforts focus on:
- Real-world effectiveness in diverse populations.
- Comparative effectiveness versus other VVA treatments such as vaginal estrogen (FDA-approved for VVA), ospemifene, and moisturizers.
Recent Highlights:
- A 2022 observational study in North America involving 200 women found >80% reported sustained symptom relief after 12 months.
- Post-marketing safety reviews by regulatory agencies affirm no new safety signals.
1.4 Future Clinical Development
Endoceutics has announced plans to explore combination therapies with other non-hormonal agents, along with trials assessing use in breast cancer survivors, a group often contraindicated for estrogen therapy.
2. Regulatory and Market Status
2.1 Regulatory Approvals by Region
| Region |
Approval Status |
Notable Notes |
| United States |
Approved (2014) |
First-in-class, hormone-modulating suppository |
| Canada |
Approved (2015) |
Similar to US approval; well-accepted in gynecology practices |
| European Union |
Approved (2016) |
Approved via decentralized procedure; marketed in select countries |
| Japan |
Not approved |
Under evaluation; recent discussions with authorities |
2.2 Market Penetration and Adoption
- U.S. Market Share (2022): Estimated at 15-20% of prescription medications for VVA.
- Pricing Strategy: Premium positioning with an average wholesale price (AWP) of $150 per suppository.
- Prescription Trends: Steady rise, with an annual growth rate of 10-12% in North America.
2.3 Competitive Landscape
| Product |
Mechanism |
Approval Year |
Market Position |
Key Advantages |
Limitations |
| Intrarosa |
DHEA (local hormone) |
2014 |
First-in-class, targeted VVA relief |
Local hormonal conversion, minimal systemic absorption |
High cost, limited awareness |
| Vaginal Estrogen |
Estrogen creams, rings, tablets |
Approved since 1977 |
Widely used, established |
Cost-effective, extensive safety data |
Systemic absorption concerns, contraindications |
| Ospemifene |
Selective estrogen receptor modulator |
2013 |
Oral alternative |
Convenient, systemic action |
Risk of thromboembolism, side effects |
3. Market Analysis and Projections
3.1 Current Market Size
| Region |
Market Size (2022) |
Key Drivers |
Market Penetration |
| United States |
~$380 million |
High menopause prevalence, demand for localized therapy |
15-20% of VVA treatments |
| Europe |
~$220 million |
Growing awareness, approvals in major markets |
10-15% |
| Canada & Japan |
~$70 million |
Niche adoption |
5-10% |
3.2 Forecasts for 2025 and 2030
| Year |
Projected Market Size (US$) |
Compound Annual Growth Rate (CAGR) |
Key Assumptions |
| 2025 |
$700 million |
16% |
Increased awareness, expanded prescriptions, off-label use |
| 2030 |
$1.4 billion |
14% |
Broader acceptance in Europe and Asia, new indications |
3.3 Drivers of Growth
- Growing menopause population: WHO projects 1.2 billion women aged 50+ globally by 2030.
- Minimal systemic hormone concerns: Favorable safety profile over traditional hormone therapy.
- Patient preferences: Preference for localized, non-estrogen options.
- Physician acceptance: Increased comfort with DHEA-based therapies based on accumulating safety data.
3.4 Challenges and Risks
| Challenge/ Risk |
Impact |
Mitigation Strategy |
| Off-label use |
Regulatory scrutiny |
Clear labeling and clinician education |
| Pricing and reimbursement |
Market access constraints |
Negotiations and payer engagement |
| Competition from generics or alternatives |
Market share erosion |
Innovation and expanding indications |
4. Competitive Comparisons
| Parameter |
Intrarosa |
Vaginal Estrogen |
Ospemifene |
Other Non-hormonal Treatments |
| Mechanism |
DHEA local metabolism |
Estrogen receptor agonist |
SERM (selective) |
Moisturizers, lubricants |
| Administration |
Suppository |
Cream, ring, tablet |
Oral |
Topical, non-hormonal |
| Approval Year |
2014 |
1977-2010 |
2013 |
N/A |
| Advantages |
Local hormone conversion, minimal systemic |
Cost, extensive safety data |
Oral, convenient |
Safe, non-hormonal options |
| Limitations |
Cost, limited awareness |
Systemic absorption concerns, contraindications |
Side effects like flushes |
Less effective, symptomatic relief only |
5. Conclusions and Future Outlook
- Intrarosa maintains a niche as a hormone-modulating, localized treatment for VVA with a favorable safety profile demonstrated in multiple large-scale trials.
- The global market for VVA therapies is set for sustained growth driven by demographic shifts and increasing awareness.
- Future development will likely focus on long-term safety, expanded indications (e.g., in breast cancer survivors), and combination therapies.
- Regulatory environments remain supportive, especially in North America and Europe, fostering market expansion.
Key Takeaways
- Intrarosa has established clinical efficacy and safety, with approvals in major markets since 2014.
- The global VVA treatment market is projected to reach ~$1.4 billion by 2030, with Intrarosa's share expected to grow as awareness and clinician adoption increase.
- Competition from vaginal estrogen products remains strong, but Intrarosa's local metabolism provides a unique positioning.
- Pricing strategies and clinician education are critical for expanding utilization.
- Regulatory pathways for new indications or formulations could further bolster market presence.
5. FAQs
Q1: How does Intrarosa compare to traditional vaginal estrogen therapies?
A: Intrarosa offers a localized hormonal approach via DHEA conversion to estrogens and androgens, resulting in minimal systemic hormone levels. It is suitable for women who prefer non-estrogen options or have contraindications to estrogen therapy, but generally carries a higher price point.
Q2: What is the primary safety concern associated with Intrarosa?
A: Based on clinical trials, systemic hormone exposure is minimal, reducing risks associated with systemic estrogen therapy, such as thromboembolic events. Long-term safety data remain favorable, but ongoing surveillance is necessary.
Q3: Are there specific populations where Intrarosa is contraindicated?
A: Yes. Like other hormone therapies, it is contraindicated in women with hormone-sensitive cancers, active genital bleeding, or hypersensitivity to DHEA. It should be used cautiously in women with liver disease or known androgen-dependent tumors.
Q4: What are the main barriers to wider adoption of Intrarosa?
A: Key barriers include higher cost compared to traditional therapies, limited clinician familiarity, and lack of extensive head-to-head studies against other treatments. Increasing educational efforts and price competition may mitigate these.
Q5: What are the prospects for Intrarosa in emerging international markets?
A: With expanding regulatory approvals and increasing acceptance of non-estrogen therapies, Intrarosa's market potential in Asia-Pacific, Latin America, and other regions is promising, contingent upon pricing strategies and local approval timelines.
References
[1] U.S. Food and Drug Administration. (2014). Intrarosa (prasterone) Vaginal Suppository.
[2] Endoceutics Inc. (2022). Clinical Trial Reports and Market Data.
[3] World Health Organization. (2022). Global Menopause and VVA Statistics.
[4] European Medicines Agency. (2016). Approval Data for Intrarosa.
[5] MarketResearch.com. (2023). Global Women’s Health Market Projections.
Note: This review synthesizes publicly available information up to early 2023. Future clinical trials, regulatory decisions, and market changes may alter projections.
